Australia’s competition watchdog is to take local units of GlaxoSmithKline and Novartis to court over alleged false or misleading marketing of pain relief gels.
The Australian Competition and Consumer Commission (ACCC) is taking action against GlaxoSmithKline Healthcare Australia and Novartis Consumer Health Australasia over what it claims are “false or misleading representations in the marketing of Voltaren Osteo Gel and Voltaren Emulgel pain relief products.”
The ACCC alleges that the companies marketed Osteo Gel as specifically formulated for treating osteoarthritis conditions and more effective than Emulgel, when the products had identical formulations. The watchdog found Osteo Gel was “sold at a significant price premium to Emulgel” in supermarkets and pharmacies.
The move by the ACCC comes after British consumer goods group Reckitt Benckiser was fined a record AU$6 million (US$4.5 million) by an Australian court in late 2016 for misleading consumers over the painkilling effects of Nurofen.
Full Content: Business Insider
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI